Medical school

CARGO Therapeutics Announces Scientific Advisory Board

Retrieved on: 
水曜日, 12月 6, 2023
Associate, Baylor University, Baylor College of Medicine, Hospital, Division, Research, Investment company, Massachusetts General Hospital, MD, Doctor of Philosophy, SAB, SAN, Therapy, Cancer, CD2, Health, Section, Dana–Farber Cancer Institute, University, Hematology, Faculty, MBBS, Royal North Shore Hospital, Patient, Boston, Harvard Medical School, MGH, Medical school, CD22, Nursing

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
  • The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
  • “The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
  • “They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
    Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .

RetinAI Joins Forces with Stephen J. Ryan Initiative for Macular Research (RIMR) AMD Consortium to Forge a Global Retinal Imaging initiative Targeting Research in AMD

Retrieved on: 
水曜日, 11月 29, 2023
School, Database, UCLA, Physician, Research, Paratriathlon, Prevalence, AMD, Disease, Health, Doheny Eye Institute, Professor, Artificial intelligence, Biomarker, Data management, RIMR, Medical school, Medical device

AMD is a significant global health concern, affecting about 170 million individuals and ranking as the third leading cause of vision loss worldwide.

Key Points: 
  • AMD is a significant global health concern, affecting about 170 million individuals and ranking as the third leading cause of vision loss worldwide.
  • The United States alone sees a prevalence of AMD similar to that of all invasive cancers combined, contributing to substantial healthcare costs.
  • The disease burden varies by region, as illustrated by studies showing differences in AMD prevalence between Western countries and China, and among ethnic groups globally.
  • “We are thrilled to be a part of the consortium and help to facilitate cutting-edge research with a shared goal of improving patient care,” he added.

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
火曜日, 11月 28, 2023
Associate, Metastasis, Therapeutic endoscopy, Partnership, Neoplasm, Division, Death, Alpha Sigma Tau, Lung, Research, Breast, Radiation, General Hospital, Data, Pancreas, Alpha, Brain, Vulva, JGH, Endoscopy, Clinical trial, News, FRCPC, Pancreatic cancer, CA19-9, Radiation therapy, Interim, Assistant, McGill University, Translational research, Medical school, Patient, Safety, Neck

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies

Retrieved on: 
月曜日, 11月 27, 2023
Drug resistance, UKRI, Cellular senescence, Metastasis, Nature Cell Biology, Protein, Medicine, ICS, Research, Chemical biology, Imperial College London, Spacecraft, COPI, CRUK, NMT, ARF1, Cancer, GSK, Notifiable disease, Laboratory, Inflammation, Cell, Phenotype, Medical school, Data, ADC, Francis Crick Institute

Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.

Key Points: 
  • Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.
  • Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.
  • Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells.
  • Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads.

China Medical University Hospital's Breakthrough Drug of 'Allogenic mRNA CAR-T' & Its GenAI 'gHi' Standing Out in Healthcare+ Expo (Taiwan) 2023

Retrieved on: 
木曜日, 12月 28, 2023
GHI, Dicarboxylic acid, Roger Hawkins (drummer), Attention, Neoplasm, Multimedia, U.S. FDA, Allogenic succession, Messenger, FDA, Lung, Breast, Mortality, Medical school, Regenerative medicine, PCR, News, Cancer, AI, Intelligence, China Medical University, Artificial intelligence, Obesity, Hospital, Geography of Taiwan, Formosa Television, Patient, Global health, Safety, Superintendent, Health, Sepsis, Vaccine

Among them, China Medical University Hospital (CMUH, Taiwan) was attracted most attention in the exposition.

Key Points: 
  • Among them, China Medical University Hospital (CMUH, Taiwan) was attracted most attention in the exposition.
  • Those items of the cutting-edge products received great attention at the Healthcare+ Expo (Taiwan) 2023.
  • In the news video of Formosa TV, Taiwan's broadcast news station, China Medical University and its Healthcare System recently showcased some of its latest innovations and tech at 2023 Healthcare+ Expo Taiwan.
  • Through the Healthcare+ Expo (Taiwan) 2023, the CMUH hopes to enhance the world's premiere medical technology innovation that has been driving improvements in global health.

Los Angeles Weight Loss Surgeon, Dr. David Davtyan, Thrilled for New FDA Approved ReShape Lifesciences® Next-Generation Lap-Band® 2.0 FLEX

Retrieved on: 
火曜日, 12月 26, 2023
School, UCLA, Bariatric surgery, Multimedia, Weight loss, FDA, Surgeon, Inland Empire, Obesity, Food, Kia, Patient, PMA, Adjustable gastric band, FLEX, Medical school, Generic drug

BEVERLY HILLS, Calif., Dec. 26, 2023 /PRNewswire-PRWeb/ -- Dr. David Davtyan, a renowned surgeon and pioneer in weight loss surgery, is delighted to announce the FDA approval of ReShape Lifesciences' groundbreaking Lap-Band® 2.0 FLEX. Dr. Davytan was one of the first surgeons in the United States to offer the Lap-Band procedure and leads The Weight Loss Surgery Center of Los Angeles, a prestigious medical weight loss clinic in Beverly Hills. Dr. Davytan has dedicated his career to helping patients battle obesity through various surgical procedures. The enhanced Lap-Band® 2.0 FLEX development effort was physician-led, including input from Dr. Davtyan, with the goal of improving the patient experience. Compared to the current Lap-Band, the Lap-Band® 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage created by the band. This minimizes discomfort caused by the passage of large food pieces through the stoma. The Lap-Band® system has long been considered the safest and most durable weight loss option for obese patients. It is particularly ideal for those who are opposed to medically managed weight loss and prefer an anatomy-preserving surgery. Using this latest advancement, The Weight Loss Surgery Center of Los Angeles looks forward to continuing their mission of transforming lives through cutting-edge, safe and effective weight loss procedures.

Key Points: 
  • Dr. David Davtyan and his team at The Weight Loss Surgery Center of Los Angeles are looking forward to offering this innovative solution to their patients.
  • BEVERLY HILLS, Calif., Dec. 26, 2023 /PRNewswire-PRWeb/ -- Dr. David Davtyan , a renowned surgeon and pioneer in weight loss surgery , is delighted to announce the FDA approval of ReShape Lifesciences' groundbreaking Lap-Band® 2.0 FLEX.
  • Dr. Davytan was one of the first surgeons in the United States to offer the Lap-Band procedure and leads The Weight Loss Surgery Center of Los Angeles, a prestigious medical weight loss clinic in Beverly Hills.
  • Kia, The Weight Loss Surgery Center of Los Angeles, 877-923-7546, [email protected] , https://weightlosssurgeryla.com/
    View original content to download multimedia: https://www.prweb.com/releases/los-angeles-weight-loss-surgeon-dr-david-...

New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation

Retrieved on: 
木曜日, 12月 21, 2023
Biology, MTR, Dermatitis, DOI, Hospital, Atopic dermatitis, Protein, FAAD, Family, Immune system, Division, Neuron, Sensation, Allergy, British Columbia Children's Hospital, Research, Cell, DRS, University of British Columbia, Sol, Disease, Tissue, Mouse, Rheumatoid arthritis, Cancer, Inflammation, Asthma, FRCPC, University, JAK, Mutation, Faculty, Hypereosinophilic syndrome, Nervous system, Gene, Lung, MBBS, Neuroinflammation, Patient, JAK1, Medical school, Diagnosis, Canada Research Chair, STAT6, Signal, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues. Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders. Details on the findings were published in the December 21, 2023, issue of the journal Cell (DOI: 10.1016/j.cell.2023.11.027).

Key Points: 
  • Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
  • Current JAK inhibitors work well against inflammation in diseases like eczema, but the study suggests a need for a nuanced approach in modulating JAK activity for conditions like asthma.
  • The study showed that activated JAK1 signaling has tissue-specific effects, including an unexpected immunoregulatory role in lung sensory neurons, where it suppresses lung inflammation.
  • In the lung neurons of the mice, the JAK1 mutant protein reduced inflammation caused by exposure to mold by producing substances that suppress inflammation.

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors

Retrieved on: 
火曜日, 12月 19, 2023
Atlas Venture, Therapeutic index, Atlas, Yale University, Cytokine, Science, Drug discovery, Medical school, Sutro Biopharma, Research, Chemistry, BeiGene, Tislelizumab, Acquisition, EGFR, File, Inflammation, Physician, Juno Therapeutics, MBA, College, Blinatumomab, Therapy, Columbia University, Lisocabtagene maraleucel, Cancer, University, Head, Feinberg School of Medicine, BMS, Harvard College, Surgeon, Medicine, Biogen, FACP, Pharmaceutical industry

GERMANTOWN, Md., Dec. 19, 2023 /PRNewswire/ -- Deka Biosciences ("Deka") today announced the appointments of Stanley Frankel, M.D., FACP, as senior clinical advisor, interim chief medical officer and scientific advisory board member, and Stuart Chaffee, Ph.D. as an independent director and chairman of the Board. Deka is a privately held biotech company developing next-generation cytokine therapies to treat cancer and inflammatory diseases based on a patient's individual immune response. Deka's lead asset, DK210 (EGFR), is currently being evaluated for the treatment of multiple solid tumors in a Phase 1 clinical trial.

Key Points: 
  • Deka is a privately held biotech company developing next-generation cytokine therapies to treat cancer and inflammatory diseases based on a patient's individual immune response.
  • Dr. Frankel joins Deka as a hematologist-oncologist with over 20 years of industry experience, including the research, clinical development, and commercialization of immuno-oncology and cellular therapies.
  • He is a non-executive director at Precision Biosciences and a member of the board of directors at Myeloid Therapeutics.
  • Earlier in his career, Dr. Chaffee served in several roles at Biogen across finance, business development, program leadership, and corporate strategy.

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
月曜日, 11月 13, 2023
Transfer, Assistant, Woman, Methodist Hospital, Research, Senior, Gynecologic Oncology (journal), Travel, University, Conference call, Risk, Gynaecology, Protein, MicroRNA, Dana–Farber Cancer Institute, Algorithm, Medical Affairs Bureau, Marketing, Metadata, AUP, COVID-19, Conference, Ovarian cancer, Harvard Medical School, University of Oxford, Brigham, CAB, Reproductive biology, Medical school, Aspira, Government, AACR, Hospital, Video game, Arms industry, Rare-earth element, Pharmaceutical industry, Birth control, Cryptocurrency, Obstetrics

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the three- and nine-month period ended September 30, 2023.

Key Points: 
  • “We are pleased to report another quarter of year-over-year growth, with revenues this quarter of $2.2 million.
  • The Company expects general and administrative expenses to remain flat for the fourth quarter of 2023.
  • Our cash balance this quarter benefited from the registered direct offering where we raised $4.7 million in gross proceeds.
  • The Company reiterates its operating cash utilization target for the second half of 2023 to between $6.0 million and $8.0 million.

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Retrieved on: 
日曜日, 11月 12, 2023
NDA, Medicine, PALO, ACM, Safety, Food, Month, Cardiology, European Society of Cardiology, CVH, AHA, Mortality, Patient, ATTR, FDA, American Heart Association, Survival, Cancer, TTR, Medical school, DSM-IV codes, Pharmaceutical industry

PALO ALTO, Calif., Nov. 12, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, at the American Heart Association (AHA) Scientific Sessions 2023. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR). In July, BridgeBio announced positive topline results from ATTRibute-CM, and in August, BridgeBio presented detailed positive results at the European Society of Cardiology Congress 2023. BridgeBio will host an investor call on Sunday, November 12 at 11:15 am ET to discuss these results.

Key Points: 
  • ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).
  • In July, BridgeBio announced positive topline results from ATTRibute-CM, and in August, BridgeBio presented detailed positive results at the European Society of Cardiology Congress 2023.
  • BridgeBio will host an investor call on Sunday, November 12 at 11:15 am ET to discuss these results.
  • “The positive results of the ATTRibute-CM study demonstrate that acoramidis improved clinical outcomes for ATTR-CM patients, even in the contemporary care setting.